LDX

LUMOS FPO [LDX]
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Healthcare · ASX Small Cap
$0.0970 -3.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when LDX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track LDX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Lagging the Small Ords index — relative strength of 0.79, underperforming its peers
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Cash positive / operating cashflow positive
  • Moderate P/S ratio (6.9x)
  • Moderate revenue growth (+16%)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (8% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (19%)
  • Turned profitable (NPAT positive from results)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.88%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-38%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 29% over the past year
Ask Scout AI about LDX
"What's driving LDX today?" "How does LDX compare to peers?" "Key risks for LDX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Section 708A Cleansing Statement
NONE Application for quotation of securities - LDX
NONE Change of Director's Interest Notice - DW

Recent ASX Announcements

2026-09-01 Section 708A Cleansing Statement
2026-09-01 Application for quotation of securities - LDX
2026-09-01 Change of Director's Interest Notice - DW
2026-08-26 Appendix 4G and Corporate Governance Statement
2026-08-25 FY26 Full Year Results Announcement PRICE SENSITIVE

Key Metrics

$91.6M
Market Cap
937K
Avg Volume
1.4x
Vol Ratio
$0.08 — $0.33
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-34.1%
ROE
-37.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 61%
LLeader vs LaggardlaggardRS: -4
IInstitutional SponsorshippassInst: 19%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:LDX vs REGLDX vs CANLDX vs BIT
Scout Pro — Deeper Analysis for LDX
Try Pro free for 30 days
Share this analysis

Track LDX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required